Forest and Almirall Report Preliminary Topline Results from the ACCORD COPD II Phase III Study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD) - Drugs.com MedNews
Links shared publicly online about this topic.
- 766total visits
Forest and Almirall Report Preliminary Topline Results from the ACCORD COPD II Phase III Study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD) - Drugs.com MedNews
Oct 29, 2010 - Forest Laboratories, Inc. (NYSE FRX) and Almirall, S.A. (ALM.MC) today announced top-line results from ACCORD COPD II, a 12-week Phase III study
View full resource at drugs.com
Tags: COPD, Disease and Condition, Drug, Forest Laboratories, Pulmonology, disease
Most Recently Shared on October 29, 2010 at 5:15 pm By:
Forest and Almirall Report Preliminary Topline Results from the ACCORD COPD II Phase III Study of aclidinium ... http://bit.ly/ayMmGp #drug
Advertisement
